Heptocellular Carcinoma (HCC) is a "silent killer". It develops unseen, often only to be found when it’s too late to save patients. It is already the third leading cause of cancer death,1 and the global incidence of HCC is increasing, especially in developed countries.2
But it doesn’t have to be that way. We refuse to let it continue as a "silent killer". We’re turning up the volume on HCC.
Healthcare is rapidly shifting, towards more personalised care that’s more in tune with patients, embracing digital technologies that enable new possibilities. At Roche, we are shaping a new class of diagnostic algorithms.
Introducing the Elecsys® GAAD in-vitro diagnostic multivariate index assay. It is a CE-marked algorithm to help you diagnose early stage HCC and save lives. Combining Elecsys® AFP and Elecsys® PIVKA-II assay results, along with gender and age, Elecsys® GAAD communicates patients’ risk factor clearly, so you may be able to evaluate earlier and save more lives.
It’s simple and intuitive to use, and can be adapted to your current workflow, so there will be no disruption to you.
Elecsys® GAAD is an in vitro diagnostic multivariate index assay intended to provide a semi-quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP assay and Elecsys® PIVKA‑II assay in human serum and plasma with gender and age. Elecsys® GAAD is intended as an aid in diagnosis of early stage Hepatocellular Carcinoma (HCC).
Elecsys® GAAD is indicated for adults who meet the following criteria: diagnosis of chronic liver disease and recommended for surveillance due to increased risk of developing HCC.
Elecsys® GAAD must be interpreted in conjunction with other diagnostic findings and clinical information in accordance with standard clinical management guidelines.